Evidence map›Paper›PMID 26003847›Full record

ArticleInternational immunopharmacology2015

Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links.

Bettina Nadorp, Hermona Soreq

Open access · hybridAbstract read
In one paragraph

Article in International immunopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bettina NadorpDepartment of Biological Chemistry, The Hebrew University of Jerusalem, Israel; Institute of Life Sciences, The Hebrew University of Jerusalem, Israel; Edmond and Lily Safra Center of Brain Science, The Hebrew University of Jerusalem, Israel; Grass Center for Bioengineering, The Hebrew University of Jerusalem, Israel.
Hermona SoreqDepartment of Biological Chemistry, The Hebrew University of Jerusalem, Israel; Institute of Life Sciences, The Hebrew University of Jerusalem, Israel; Edmond and Lily Safra Center of Brain Science, The Hebrew University of Jerusalem, Israel. Electronic address: hermona.soreq@mail.huji.ac.il.
Hebrew University of Jerusalem · IL

Funding

European Research Council 321501
6 · The paper itself

Abstract

The intestinal tissue notably responds to stressful, cholinergic and innate immune signals by microRNA (miRNA) changes, but whether and how those miRNA regulators modify the intestinal cholinergic and innate immune pathways remained unexplored. Here, we report changes in several miRNA regulators of cholinesterases (ChEs) and correspondingly modified ChE activities in intestine, splenocytes and the circulation of mice exposed to both stress and canonical or alternative Toll-Like Receptor 9 (TLR9) oligonucleotide (ODN) aptamer activators or blockers. Stressful intraperitoneal injection of saline, the anti-inflammatory TLR9 agonist mEN101 aptamer or the inflammation-activating TLR9 aptamer ODN 1826 all increased the expression of the acetylcholinesterase (AChE)-targeting miR-132. In comparison, mEN101 but neither ODN 1826 nor saline injections elevated intestinal miR-129-5p, miR-186 and miR-200c, all predicted to target both AChE and the homologous enzyme butyrylcholinesterase (BChE). In cultured immune cells, BL-7040, the human counterpart of mEN101, reduced AChE activity reflecting inflammatory reactions in a manner preventable by the TLR9 blocking ODN 2088. Furthermore, the anti-inflammatory BL-7040 TLR9 aptamer caused reduction in nitric oxide and AChE activity in both murine splenocytes and human mononuclear cells at molar concentrations four orders of magnitude lower than ODN 1826. Our findings demonstrate differential reaction of cholinesterase-targeting miRNAs to distinct TLR9 challenges, indicating upstream miRNA co-regulation of the intestinal alternative NFκB pathway and cholinergic signaling. TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases.

Indexed as

AcetylcholineAcetylcholinesteraseAnimalsCell LineGene Expression RegulationHumansIntestinal MucosaLeukocytes, MononuclearMacrophagesMaleMiceMicroRNAsModels, MolecularOligonucleotidesProtein BindingProtein ConformationAcetylcholineAcetylcholinesteraseMicroRNAsOligonucleotidesTlr9 protein, mouseToll-Like Receptor 9AcetylcholinesteraseButyrylcholinesteraseIntestinal inflammationMicroRNANon-neuronal acetylcholineToll-Like Receptor 9

Identifiers

PMID26003847
PMCPMC4646847
OpenAlexW322273347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.